Primaquine

Administration
  • Type: Antimalarial, anti-PCP
  • Dosage Forms:
  • Routes of Administration: oral
  • Common Trade Names:

Adult Dosing
  • PCP pneumonia, HIV+ : 15-30mg PO daily with clindamycin
  • Malaria treatment: 26.3-52.6mg PO daily in combination with an additional anti-malarial agent
  • Malaria prophylaxis: 52.6mg PO daily starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Pediatric Dosing
  • Malaria treatment: 0.8 mg/kg PO daily (max 52.6mg daily) in combination with an additional anti-malarial agent
  • Malaria prophylaxis: 0.8 mg/kg PO daily (max 52.6mg daily) starting 1-2 days prior to arrival in endemic area until 7-14 days after departure

Special Populations
  • Pregnancy Rating: D
  • Lactation risk: Infant risk cannot be ruled out
  • Renal dosing:
  • Hepatic dosing:

Contraindications
  • Allergy to class/drug
  • Concomitant use with other potentially hemolytic or myeloid suppressing drugs
  • Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)

Adverse Reactions

Serious
  • Hemolytic anemia, leukopenia
  • Methemoglobinemia

Common
  • Nausea, abdominal pain

Pharmacology
  • Half-life: 4-7 hours
  • Metabolism:
  • Excretion:

Mechanism of Action
  • Eliminates tissue infection, thus preventing erythrocytic forms of parasite

See Also

References
    This article is issued from Wikem. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.